Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months. - Université de Bretagne Occidentale Accéder directement au contenu
Poster De Conférence Année : 2019

Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.

Domaines

Immunologie

Geneviève Michel  : Connectez-vous pour contacter le contributeur

https://hal.univ-brest.fr/hal-02151122

Soumis le : vendredi 7 juin 2019-16:59:02

Dernière modification le : mercredi 17 janvier 2024-09:52:07

Fichier non déposé

Dates et versions

hal-02151122 , version 1 (07-06-2019)

Identifiants

  • HAL Id : hal-02151122 , version 1

Citer

Alain Saraux, Thomas Barnetche, Guy Baudens, Isabelle Idier, Flore Delaporte, et al.. Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.. EULAR 2019, Jun 2019, MADRID, Spain. ⟨hal-02151122⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-BREST IMMUNO IBSAM
26 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More